AMD awareness: Close focus on preserving vision
February 21, 2020
Awareness of the development of age-related macular degeneration (AMD) has been increasing slowly with the recognition of the advancing age of the population.
Recent Content
PRN ranibizumab outcomes over the long term in real world
February 20, 2020
Nearly 50% of eyes with wet age-related macular degeneration (AMD) have stable or improved vision after long-term, 8-year pro re nata (PRN) treatment with ranibizumab, according to a group of U.K. clinicians.
Consensus group redefines, standardizes AMD classifications
February 13, 2020
An internationally renowned working group of retina specialists, ocular imaging experts, and ocular pathologists have suggested standardizing definitions for age-related macular degeneration (AMD) and its subtypes.
Diagnosing AMD for the non-retina specialist
February 13, 2020
Optometry Australia has developed an AMD chairside reference in consultation with a member-based working group comprised of experienced practitioners.
Stem cell transplantation: Restoring vision in AMD may be possible
February 10, 2020
Given the high incidence of age-related macular degeneration (AMD)—with some 10 to 11 million patients affected, 2 million of which have severe visual loss—the need for treatments to restore vision is clear.
Exploring safety of stem cells for dry AMD
February 9, 2020
Researchers at the National Eye Institute (NEI) are launching a clinical trial to test the safety of a novel patient-specific stem cell-based therapy to treat geographic atrophy (GA), the advanced dry form of age-related macular degenerat
What non-retina specialists need to know about dry AMD
February 7, 2020
Age-related macular degeneration (AMD) is the leading cause of blindness worldwide among the elderly, and its prevalence is expected to increase as the population ages.1
Connect the dots: Diagnosing, managing multifocal choroiditides
January 31, 2020
The various multifocal choroidopathies differ in course, prognosis, and treatment. While the prognoses do differ, they are hopeful with early treatment in most cases.
AMD: What newly diagnosed patients need to know
January 31, 2020
Numerous websites are designed to raise awareness about age-related macular degeneration (AMD), some sponsored by the National Eye Institute (NEI), others by disease-specific foundations, and others by industry.
Researchers identify biomarkers for selecting AMD patients for TES protocol
January 31, 2020
In age-related macular degeneration (AMD), treat-and-extend regimens, along with the treat-extend-stop (TES) protocol, have shown comparable efficacy to fixed dosing.
